The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation
Clinical trial NCT05102292 · UNKNOWN
Trial details
- NCT number
- NCT05102292
- Sponsor
- Shanghai Henlius Biotech
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-10
- Primary completion
- 2024-06-30
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.